Michael Grey - Reneo Pharmaceuticals Founder Chairman
| RPHMDelisted Stock | USD 18.20 1.40 8.33% |
Insider
Michael Grey is Founder Chairman of Reneo Pharmaceuticals
| Age | 71 |
| Phone | 858 283 0280 |
| Web | https://reneopharma.com |
Michael Grey Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Grey against Reneo Pharmaceuticals stock is an integral part of due diligence when investing in Reneo Pharmaceuticals. Michael Grey insider activity provides valuable insight into whether Reneo Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Reneo Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Reneo Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Grey over three months ago Disposition of 50000 shares by Michael Grey of Reneo Pharmaceuticals at 1.97 subject to Rule 16b-3 | ||
Michael Grey over a year ago Bona fide gift to Michael Grey of 50000 shares of Reneo Pharmaceuticals subject to Section 16 | ||
Michael Grey over a year ago Acquisition by Michael Grey of 17500 shares of Reneo Pharmaceuticals subject to Rule 16b-3 | ||
Michael Grey over a year ago Acquisition by Michael Grey of 30000 shares of Spruce BiosciencesInc subject to Rule 16b-3 |
Reneo Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3372) % which means that it has lost $0.3372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.54) %, meaning that it created substantial loss on money invested by shareholders. Reneo Pharmaceuticals' management efficiency ratios could be used to measure how well Reneo Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Reneo Pharmaceuticals currently holds 973 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Reneo Pharmaceuticals has a current ratio of 15.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Reneo Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Anne Heatherington | Summit Therapeutics PLC | N/A | |
| Divya Chari | Summit Therapeutics PLC | 56 | |
| Stephanie Yao | Kronos Bio | N/A | |
| Federico MD | Apellis Pharmaceuticals | 50 | |
| Keith MD | Prime Medicine, Common | 70 | |
| Michelle Avery | Summit Therapeutics PLC | N/A | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Klaus Frueh | Vir Biotechnology | 64 | |
| Howard Horn | Vir Biotechnology | 46 | |
| Ellen MBA | Werewolf Therapeutics | 48 | |
| Kerry Whalen | Cullinan Oncology LLC | N/A | |
| BCh BM | Kronos Bio | 40 | |
| Andrew Hirsch | C4 Therapeutics | 53 | |
| Ankur Dhingra | Summit Therapeutics PLC | 47 | |
| Lance Laing | Celcuity LLC | 62 | |
| Dabt Ph | Celcuity LLC | 67 | |
| Jason Kelly | Ginkgo Bioworks Holdings | 43 | |
| Kyle Piskel | Adaptive Biotechnologies Corp | 40 | |
| George Scangos | Vir Biotechnology | 76 | |
| Ann Lee | Prime Medicine, Common | 62 | |
| Marie Fallon | Ginkgo Bioworks Holdings | N/A | |
Management Performance
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 |
Reneo Pharmaceuticals Leadership Team
Elected by the shareholders, the Reneo Pharmaceuticals' board of directors comprises two types of representatives: Reneo Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reneo. The board's role is to monitor Reneo Pharmaceuticals' management team and ensure that shareholders' interests are well served. Reneo Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reneo Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gregory Flesher, CEO President | ||
| Alejandro MD, Chief Officer | ||
| Ashley JD, Chief Officer | ||
| Wendy MBA, Consultant | ||
| Vineet Jindal, Consultant | ||
| Michael Cruse, Chief Officer | ||
| Jennifer Lam, Principal Officer | ||
| Lynn Purkins, Senior Development | ||
| Michael Grey, Founder Chairman |
Reneo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Reneo Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (15.01 M) | |||
| Shares Outstanding | 3.34 M | |||
| Shares Owned By Insiders | 5.19 % | |||
| Shares Owned By Institutions | 87.75 % | |||
| Number Of Shares Shorted | 3.4 M | |||
| Price To Book | 0.79 X | |||
| EBITDA | (82.23 M) | |||
| Net Income | (77.39 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in Reneo Stock
If you are still planning to invest in Reneo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reneo Pharmaceuticals' history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Global Correlations Find global opportunities by holding instruments from different markets |